Corporate and regulatory developments over the Christmas period
Myovant and Pfizer showed that deal-making was not taking a Christmas break, but for Celgene CVR holders the dream is almost over. And vaccine approvals gained pace.
A new setting for antigen testing
It is vital that the first authorised at-home, non-prescription Covid-19 antigen test be used in the right way.
The promise and the perils of antigen testing
A new UK plan to use antigen tests for wide-scale screening for Covid-19 may not be the easy win the government is seeking.
Bristol bets big on Myokardia
The $13.1bn price suggests that Bristol could be banking on mavacamten’s potential outside rare diseases.
Lilly leads the Covid antibody charge
LY-CoV555 shows promising signs for the antibody approach, with Regeneron not far behind.
ESC 2020 – Myokardia odds-on for first approval in heart muscle disease
Positive phase III data in hand, Myokardia heads to the FDA.
Biopharma shares shake off the pandemic
Global drug stocks enthusiastically joined the recovery on the financial markets in the second quarter, more than offsetting earlier declines.
Here come the anti-Covid antibodies
Behind Lilly’s LY-CoV555 come numerous biopharma antibody projects bidding to enter clinical development.
